UBS Maintains Buy on Solventum, Raises Price Target to $101
UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga